CoImmune Archives | Page 2 of 2

CoImmune, Inc. Announces FDA Approval of its IND Application to Conduct a Phase 2b Clinical Trial with CMN-001 in Advanced RCC Patients

DURHAM, N.C., Feb. 19 (Korea Bizwire) — CoImmune, Inc. announced today that the FDA approved its investigational new drug application (IND) and that it is cleared to move forward with a Phase 2b clinical trial in advanced metastatic renal cell carcinoma (mRCC). CMN-001, formerly known as AGS-003, is a dendritic cell-based immunotherapy custom matched to [...]

CoImmune Inc., a US-based Clinical-stage Biotech, and Formula Pharmaceutical Inc. Agree to Merge in an All-stock Transaction

DURHAM, N.C., Jan. 15 (Korea Bizwire) — CoImmune, Inc. and Formula Pharmaceuticals, Inc. announced today the merger between the two companies, bringing together two therapeutic immuno-oncology platforms. Upon completion of the merger of Formula Pharmaceuticals into CoImmune, bringing forth access to all of Formula Pharmaceuticals’ tangible and intangible assets, the merged company will continue to [...]